Harmony Biosciences Reports Officer/Director Changes & Compensatory Info

Ticker: HRMY · Form: 8-K · Filed: 2024-05-03T00:00:00.000Z

Sentiment: neutral

Topics: management-change, compensation, corporate-governance

Related Tickers: HRMY

TL;DR

Harmony Bio (HRMY) filed an 8-K detailing exec/director changes and compensation plans.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on May 3, 2024, reporting events as of May 1, 2024. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

Changes in key personnel and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in executive and director positions, along with details on compensatory arrangements, can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

FAQ

What specific officer or director positions were affected by the changes reported in this 8-K?

The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify the names or exact positions within the provided text.

Are there any details about new compensatory arrangements for officers mentioned?

Yes, the filing lists 'Compensatory Arrangements of Certain Officers' as a reported item, suggesting details on such arrangements are included.

When was the earliest event reported in this filing?

The earliest event reported was as of May 1, 2024.

What is the primary purpose of this 8-K filing for Harmony Biosciences?

The primary purpose is to report significant corporate events including changes in directors/officers and related compensation, as well as to file financial statements and exhibits.

What is Harmony Biosciences' Standard Industrial Classification (SIC) code?

Harmony Biosciences Holdings, Inc. has a Standard Industrial Classification (SIC) code of 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001558370-24-006594.txt : 20240503 0001558370-24-006594.hdr.sgml : 20240503 20240503080013 ACCESSION NUMBER: 0001558370-24-006594 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240501 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24910825 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240501x8k.htm 8-K 0001802665 false 0001802665 2024-05-01 2024-05-01 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): May 1, 2024 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. ​ The Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Offic

View on Read The Filing